Robert Castellucci, MD
Endocrinology, Diabetes & Metabolism · Richmond, VANPI 1952336026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 522 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 43 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Reporting peaked in 2019 at $2,393 and has fallen 64.4% since, to $851 in 2025.
Across 522 payments — averaging $13.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$588
- AstraZeneca$468
- Amgen$445
- Insulet Corporation$384
- Amarin Pharma, Inc.$336
- plus $3K from 37 others
What the payments were for
- Food & beverage$7,18099%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,226 in reported general payments places this provider in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 457 | $717,646 |
| JardianceEmpagliflozin | 199 | $216,916 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 129 | $151,535 |
| TrulicityDulaglutide | 104 | $150,793 |
| Tresiba Flextouch U-200Insulin Degludec | 123 | $145,934 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $110,058 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 43 | $107,177 |
| FarxigaDapagliflozin Propanediol | 74 | $93,018 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 77 | $79,082 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 122 | $74,361 |
| Tresiba Flextouch U-100Insulin Degludec | 96 | $67,991 |
| MounjaroTirzepatide | 56 | $65,292 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 185 | $64,617 |
| JanuviaSitagliptin Phosphate | 56 | $58,754 |
| JanumetSitagliptin Phos/Metformin Hcl | 58 | $49,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Tresiba, Novolog | $1,838 | $853,383646 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $309 | $318,752302 claims |
| MerckJanumet Xr, Januvia, Janumet | $67 | $260,212243 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Lyumjev, Humalog Mix 75-25 | $588 | $257,054308 claims |
| AstraZenecaFarxiga | $468 | $93,01874 claims |
| AbbVieSynthroid | $57 | $31,685383 claims |
| Sanofi-aventis U.S. LLCLantus | $321 | $14,42776 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $183 | $11,481898 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Richmond
- Shea PuttkammerRichmond$24K
- Robert AdlerRichmond$10K
- Ranjodh GillRichmond$8K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.